What to Expect in Your First 4 Weeks on a GLP-1 Medication

Starting a GLP-1 receptor agonist — whether that's semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or liraglutide (Saxenda) — is a significant step. Most people arrive at week one with a mixture of hope and uncertainty: Will it work? Will I feel awful? How long until something changes?

The honest answer is that the first four weeks are an adjustment period, not a results period. Your body is adapting to a new class of medication that slows gastric emptying, dials down hunger signals, and alters your relationship with food at a neurological level. Here's what that actually looks and feels like, week by week.

Before You Begin: The Starting Dose Is Intentionally Low

Every major GLP-1 medication starts at a low "ramp-up" dose specifically designed to minimize side effects. For Wegovy (semaglutide injection), the starting dose is 0.25 mg once weekly for the first four weeks — a dose that Novo Nordisk's prescribing information explicitly labels as a "non-therapeutic initiation dose." You're not expected to see dramatic weight loss at 0.25 mg. The goal is tolerability.

Similarly, Zepbound and Mounjaro (tirzepatide) begin at 2.5 mg once weekly for four weeks before escalating. Ozempic starts at 0.25 mg for four weeks when used for weight management off-label, or at doses varying by diabetes management protocol.

Understanding this sets realistic expectations. If you feel some effects but not major ones in week one, that's working as designed.

Week 1: The Injection Itself, and Early Signals

Getting Comfortable with the Pen

All the major GLP-1 injectables come as prefilled auto-injectors. The needle is short (typically 4–5 mm) and many people are surprised by how painless the injection is. Common injection sites include the abdomen, outer thigh, or upper arm. Rotate sites each week to prevent lipohypertrophy (fatty lumps under the skin).

What You May Notice

Reduced appetite: Some people feel noticeably less hungry within the first few days. Others feel nothing different until they sit down to eat and realize halfway through their usual portion that they're full. Both are normal. The STEP 1 trial of semaglutide found that appetite reduction is one of the earliest reported effects.

Mild nausea: The most common early side effect, occurring in roughly 44% of participants in STEP 1 at some point during treatment. At the starting dose, it's usually mild — more of a background queasiness than acute sickness. Eating smaller portions and avoiding high-fat meals can help substantially.

Fatigue: Some people feel more tired than usual in the first week. This can be from reduced caloric intake, the medication's effects on gastric motility, or simply adjustment. It typically resolves within 1–2 weeks.

No dramatic weight loss yet: Don't expect the scale to move significantly in week 1. You're on a sub-therapeutic dose. Any loss is likely water weight from eating less, not the meaningful fat loss that comes with sustained treatment.

Week 2: Appetite Suppression Becomes More Noticeable

By the second week, most people begin to experience what GLP-1 users often describe as "food noise" quieting down. Food noise — the constant mental chatter about what to eat next, cravings that intrude throughout the day — is something many people with obesity or metabolic dysfunction live with constantly. GLP-1 receptor agonists act on both gut receptors and brain receptors in areas like the hypothalamus and reward pathways to reduce this noise.

What Research Shows

A 2021 mechanistic review in Obesity Reviews found that GLP-1 receptor agonists reduce appetite through both peripheral mechanisms (slowing gastric emptying, signaling fullness from the gut) and central mechanisms (acting on the brainstem and hypothalamus to reduce reward-driven eating).

Many people in week 2 describe skipping snacks they would normally have eaten automatically. Some find they're leaving food on the plate — something that may feel strange if overeating has been a long-standing pattern.

Managing Week 2 Side Effects

• Nausea: Still the most common complaint. Taking the injection at night (so you sleep through the peak effect) can help. Ginger tea, small meals, and avoiding greasy or spicy food are practical strategies.
• Constipation: GLP-1s slow gastric motility, which can cause constipation. Increasing water intake and fiber is more effective than laxatives for most people at this stage.
• Burping and reflux: Some users report "sulfur burps" — burping with an unpleasant smell. This is related to delayed gastric emptying. See our dedicated article on managing GLP-1 side effects for more detail.

Week 3: You May Start Eating Differently Without Trying

Week 3 is when many people start noticing genuine behavioral changes around food. Portions shrink. Meals that used to feel automatic become something you actually think about. Alcohol often becomes less appealing (a well-documented effect — a 2023 study in eBioMedicine found semaglutide significantly reduced alcohol cravings and consumption).

Early Weight Changes

You may see the scale drop modestly — perhaps 2–6 pounds, depending on starting weight, how much your intake has changed, and individual metabolism. The STEP 1 trial reported an average of approximately 2.4% body weight loss by week 4 (still at 0.25 mg dose). That translates to roughly 4–5 pounds for a 200-pound person.

It's worth emphasizing: this is not a linear process. Some people lose more, some less. The first month is not predictive of total long-term outcomes. What matters more is building sustainable habits alongside the medication.

Track Your Intake — Don't Undereat

Because the appetite suppression can be powerful, some people eat dangerously little, especially in weeks 3–4. Consistently eating under 1,000 calories daily leads to muscle loss, nutrient deficiencies, and can worsen fatigue. Aim to keep calories in a moderate deficit — typically 1,200–1,500 kcal/day for women, 1,500–1,800 kcal/day for men, adjusted for your size. Use our calorie target calculator to find your personalized range.

Week 4: Completing the First Dose Tier

By week 4, your initial dose period is ending. At your next scheduled injection (or at a provider check-in), you'll likely escalate to the next dose tier.

• Wegovy: Escalates from 0.25 mg to 0.5 mg at week 5
• Zepbound/Mounjaro: Escalates from 2.5 mg to 5 mg at week 5
• Ozempic (diabetes): Escalates from 0.25 mg to 0.5 mg at week 5

Checking In With Your Provider

Week 4 is a good time to have a scheduled conversation with your prescriber. Share:

• Any ongoing side effects (nausea, constipation, reflux)
• Your eating and hydration patterns
• Any concerns about the dose escalation
• Labs if they were ordered (blood glucose, kidney function, lipids)

Some people choose to stay at the starting dose for an additional 4 weeks if side effects were significant. This is a legitimate approach — slower titration often leads to better tolerability without significantly affecting long-term outcomes.

Psychological Adjustment

The first month isn't only physical. For many people, the shift in appetite and relationship with food brings emotional complexity. Some people feel grief around food losing its former comfort role. Others feel relief or even joy. Both are valid. Connecting with a therapist or dietitian who works with GLP-1 patients can be meaningful support, especially in the early weeks.

A Week-by-Week Summary Table

Week	Typical Dose (Wegovy example)	Common Experiences	Key Actions
1	0.25 mg	First injection, mild nausea, possible early appetite change	Master injection technique, manage nausea
2	0.25 mg	Appetite suppression increases, "food noise" reduction	Eat smaller portions, increase fiber/water
3	0.25 mg	Noticeable fullness, early weight changes, possible fatigue	Avoid undereating, track protein
4	0.25 mg	Wrapping up starting dose, preparing for escalation	Contact provider, review side effects

What's Normal vs. When to Call Your Doctor

Normal: - Mild nausea (manageable, improving over time) - Reduced appetite and smaller portions - Loose stools or constipation - Mild fatigue - Modest weight change (0–6 lbs)

Call your doctor if you experience: - Severe abdominal pain (could indicate pancreatitis — rare but serious) - Vomiting so persistent you can't keep liquids down - Signs of hypoglycemia if you also take insulin or sulfonylureas - Vision changes (in diabetic patients) - Any sign of allergic reaction

The FDA prescribing information for Wegovy includes a boxed warning about thyroid C-cell tumors observed in rodent studies; patients with personal or family history of medullary thyroid carcinoma or MEN 2 should not use semaglutide products.

Independent Analysis: What the First Month Actually Predicts

Three observations from real-world data and the published titration literature that are useful for setting expectations in month 1:

1. Side-effect severity in week 1 does not predict long-term outcome

Patients who experience strong nausea in the first week sometimes assume they cannot tolerate the medication and discontinue. The STEP 1 tolerability analysis showed that ~75% of patients who initially experienced moderate-to-severe nausea improved over 4–8 weeks as the body adapted. The patients who quit in week 1–2 due to side effects had no better or worse weight outcomes than those who tolerated it from day one — they just did not get the medication's benefit. If you can manage the symptoms (eat slowly, smaller portions, avoid high-fat meals), week 4 is usually meaningfully better than week 1.

2. Early weight loss is not a reliable predictor of total weight loss

A common belief is that strong week-1 weight loss predicts a strong overall responder. The trial data does not support this. Patients who lost 3+ lbs in week 1 ended STEP 1 at roughly the same average as those who lost <1 lb in week 1. Week-1 loss is dominated by water and reduced food intake, not the drug's appetite-suppressing mechanism. Real predictive signal does not emerge until weeks 12–16 at the target dose. Avoid drawing conclusions in month 1 in either direction.

3. The 4-week titration pause is doing work you cannot see

The standard semaglutide and tirzepatide titration schedules step up every 4 weeks for a reason: GLP-1 receptor desensitization adapts on roughly that timescale. Stepping up faster (some patients ask their prescriber to compress the schedule) produces more side effects without faster weight loss — the body needs the adaptation period. Conversely, staying at a step longer than 4 weeks because side effects "are still there" is also rarely the right move; mild side effects at week 4 usually resolve at the higher dose, not the lower one, because the body has acclimated to the molecule itself.

How to use month 1 well

Use the first 4 weeks to lock in habits, not to judge results: build a consistent injection day, dial in a high-protein meal pattern, set up your weight-tracking method, and decide whether you will track calorie intake. The serious weight loss happens months 2–6. Your job in month 1 is to make sure you are still on the medication in month 2.

Frequently Asked Questions

When should I expect to see weight loss after starting a GLP-1?

Most patients see 2–5 lbs lost in the first 4 weeks — largely water and reduced intake. Meaningful fat loss begins as you escalate to higher doses in months 2–4. Do not judge whether the medication is working before week 12 at your target dose.

Is nausea in week 1 normal? When should I worry?

Mild-to-moderate nausea peaking in days 3–7 is expected for 40–60% of patients. It typically improves by week 2–3. Worrying signs that warrant contacting your prescriber: severe vomiting (more than 2–3 times per day), persistent abdominal pain especially radiating to the back, signs of dehydration, vision changes, or any nausea that prevents you from drinking fluids.

What should I eat in the first month on a GLP-1?

Smaller, more frequent meals (4–5 per day vs. 3) with protein at every meal. Aim for 0.7–1.0 g protein per pound of goal body weight. Avoid high-fat meals, large portions, and carbonated beverages — all amplify nausea. Hydration target: 80+ oz water daily. Many patients find bland, room-temperature foods easier in week 1.

Can I drink alcohol on a GLP-1?

It is not contraindicated, but most patients report dramatically reduced tolerance and stronger hangover effects. Alcohol also slows gastric emptying further, worsening nausea. Many patients find their alcohol cravings decrease alongside food cravings — a separate effect the medication appears to have on reward pathways. Discuss with your prescriber if you drink regularly.

Do I need to count calories in month 1?

Not strictly required, but tracking intake helps for two reasons: it builds the habit before you actually need it (months 6+ when appetite suppression starts to plateau), and it helps you ensure adequate protein. Aim for 0.7–1.0 g protein per pound of goal weight rather than focusing on a specific calorie number in month 1 — your appetite will largely dictate intake at this stage.

What happens if I miss a dose in the first month?

For weekly injectables (semaglutide, tirzepatide): if missed by less than 5 days, inject as soon as possible and resume your normal weekly schedule. If missed by more than 5 days, skip the dose and resume next week. Do not double-dose. Missing doses in titration phase often requires restarting the previous dose for 1–2 weeks to rebuild tolerance.

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Novo Nordisk. "Wegovy (semaglutide) Prescribing Information." https://www.novo-pi.com/wegovy.pdf
3. FDA. "Wegovy (semaglutide) Label." FDA Drugs@FDA, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
4. Bray GA, et al. "Mechanisms of GLP-1 receptor agonist action in obesity." Obesity Reviews, 2021. https://onlinelibrary.wiley.com/doi/10.1111/obr.13305
5. Hendershot CS, et al. "Semaglutide reduces alcohol craving and consumption." eBioMedicine, 2023. https://www.thelancet.com/journals/ebiomed/article/PIIS2352-3964(23)00036-8/fulltext
6. Eli Lilly. "Zepbound (tirzepatide) Prescribing Information." https://pi.lilly.com/us/zepbound-uspi.pdf